High Dose Ascorbic Acid w/ Melphalan
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
What's the purpose of the trial?
The purpose of this research is to evaluate whether HDAA in combination with a single dose of 100 mg/m2 IV melphalan followed by autologous stem cell transplantation (ASCT) is safe and effective for subjects with relapsed refractory multiple myeloma.
Accepting patients
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Melphalan is a chemotherapy medication used in the treatment of different cancers.
- Vitamin C is an antioxidant that is found in many different kinds of foods. Researchers are studying whether high doses of Vitamin C may help cancer medications to work more effectively.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.